Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study.
Bavieri A, Nizzoli ME, Tucci A, Zilioli VR, Olivieri J, Bianchi B, Rosaria MG, Annibali O, Bari A, Casaluci GM, Cimminiello M, Di Renzo N, Cavallo F, Pavone V, Mannarella C, Arcari A, Alessandro M, Anastasia A, Tarantino V, Neri A, Gentile M, Morabito F, Luminari S. Bavieri A, et al. Among authors: nizzoli me. Hemasphere. 2024 Dec 10;8(12):e70049. doi: 10.1002/hem3.70049. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39698333 Free PMC article. No abstract available.
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Perrone T, Re F, Galimberti S, Gini G, Capponi M, Vitolo U, Usai SV, Stefani PM, Ballerini F, Liberati AM, Pennese E, Pastore D, Skrypets T, Catellani H, Marcheselli L, Federico M, Luminari S. Nizzoli ME, et al. Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28. Hematol Oncol. 2023. PMID: 37246287 Clinical Trial.
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, Talami A, Murru R, Khurana A, Mwangi R, Deodato M, Cencini E, Re F, Visco C, Feldman AL, Link BK, Delamain MT, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano CC, Pennese E, Habermann TM, Marcheselli L, Han S, Reis IM, Paulli M, Lossos IS, Cerhan JR, Luminari S. Arcaini L, et al. Among authors: nizzoli me. EClinicalMedicine. 2024 Apr 11;72:102592. doi: 10.1016/j.eclinm.2024.102592. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38633575 Free PMC article.
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L, Criscuolo M, Broccoli A, Piciocchi A, Varettoni M, Galli E, Anastasia A, Cantonetti M, Trentin L, Kovalchuk S, Orsucci L, Frustaci A, Spolzino A, Volpetti S, Annibali O, Storti S, Stelitano C, Marchesi F, Offidani M, Casadei B, Nizzoli ME, De Luca ML, Fianchi L, Motta M, Guarnera L, Simonetti E, Visentin A, Vassallo F, Deodato M, Sarlo C, Olivieri A, Falini B, Pulsoni A, Tiacci E, Zinzani PL. Pagano L, et al. Among authors: nizzoli me. Blood Cancer J. 2022 Jul 19;12(7):109. doi: 10.1038/s41408-022-00702-9. Blood Cancer J. 2022. PMID: 35853850 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112162
[No title available]
[No authors listed] [No authors listed] PMID: 39112421
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study.
Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, Ciavarella S, Vegliante MC, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S. Durmo R, et al. Among authors: nizzoli me. Hematol Oncol. 2022 Oct;40(4):645-657. doi: 10.1002/hon.3025. Epub 2022 May 30. Hematol Oncol. 2022. PMID: 35606338 Free PMC article.
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Argnani L, Broccoli A, Pellegrini C, Fabbri A, Puccini B, Bruna R, Tisi MC, Masia F, Flenghi L, Nizzoli ME, Musso M, Salerno M, Scalzulli PR, Dessi' D, Ferrarini I, Pennese E, Lucchini E, Rossi FG, Minoia C, Gherlinzoni F, Musto P, Patti C, Stefoni V, Zinzani PL. Argnani L, et al. Among authors: nizzoli me. Hemasphere. 2022 Nov 11;6(12):e798. doi: 10.1097/HS9.0000000000000798. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398133 Free PMC article.
16 results